Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
BlackRock, Inc. reports beneficial ownership of common stock of X4 PHARMACEUTICALS INC. BlackRock holds 5,529,573 shares, representing 5.9% of the outstanding common stock. It has sole voting powersole dispositive power
Various underlying clients and accounts have rights to dividends and sale proceeds from these shares, but no single underlying interest exceeds five percent of X4 PHARMACEUTICALS INC’s total outstanding common stock.
X4 Pharmaceuticals Chief Financial Officer David Kirske sold 8,543 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $4.2641 per share, in multiple trades between $4.21 and $4.31.
According to the filing, the sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award. After this transaction, Kirske directly owns 167,750 shares of X4 Pharmaceuticals common stock, including 96,627 shares represented by restricted stock units.
X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation. The award covers 110,000 shares of common stock with an exercise price of $4.085 per share and expires on July 1, 2036. According to the disclosure, these options were granted at no cost on the grant date and will vest in full on the one-year anniversary of the grant date, as long as Gold continues providing services through that date. Following this award, Gold is reported to hold stock options covering 110,000 shares directly.
X4 Pharmaceuticals, Inc. director Gold Kelly has filed an initial statement of beneficial ownership on Form 3 for X4 Pharmaceuticals, Inc. This filing lists Kelly as a director and does not report any insider transactions or derivative positions in the company’s securities.
X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, expanding its board from five to six members. She will serve as an independent director and join the Board’s Audit Committee.
Gold is currently Chief Financial Officer of CAMP4 Therapeutics and previously held senior finance and corporate development roles at CAMP4 and Biogen, as well as investment banking roles at Deutsche Bank. She holds dual bachelor’s degrees in life sciences and mechanical engineering from Queen’s University and an MBA from MIT Sloan. X4 highlights her financial leadership, capital markets experience and scientific background as aligned with its focus on rare hematology diseases and the continued development of mavorixafor, which is approved in the U.S. and EU as XOLREMDI for WHIM syndrome.
X4 Pharmaceuticals amendment to Schedule 13G/A reports that Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. each beneficially own 6,889,163 shares, representing 7.3% of Common Stock based on 94,319,696 outstanding shares as of May 1, 2026. The filing states the Master Fund directly holds 6,737,648 shares and 151,515 Warrants immediately exercisable for Common Stock, subject to a Beneficial Ownership Limitation that caps ownership at 9.99%.
The reporting persons disclose shared voting and dispositive power over the reported shares and note Perceptive Advisors acts as investment manager to the Master Fund, with Joseph Edelman as managing member.
X4 Pharmaceuticals, Inc. filed an amended current report to correct a typographical error in a prior disclosure about its Class III director nominees, confirming that Murray W. Stewart, M.D. was elected rather than Michael S. Wyzga. The filing also reports final voting results from the May 11, 2026 annual stockholder meeting.
Stockholders approved increasing the shares available under the Second Amended and Restated 2017 Equity Incentive Plan by 1,500,000 shares and ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. They also approved, on a non-binding basis, the compensation of the company’s named executive officers.
X4 Pharmaceuticals Chief Financial Officer David Kirske reported an open-market sale of common stock. On May 12, 2026, he sold 16,961 shares of X4 Pharmaceuticals stock at a weighted average price of $4.2934 per share. According to the footnotes, this sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award, making it a largely tax-driven transaction rather than a discretionary portfolio move. After the sale, Kirske directly owned 176,293 shares, of which 128,836 shares are in the form of restricted stock units, so he continues to hold a substantial equity stake in the company.